# NCT01668719 (NCT01668719)

> S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01668719
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: SWOG Cancer Research Network
- Conditions: DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; DS Stage III Plasma Cell Myeloma
- Interventions: Bortezomib; Dexamethasone; Elotuzumab; Laboratory Biomarker Analysis; Lenalidomide
- Enrollment: 142
- Primary outcome: Phase I: Maximum Tolerated Dose (MTD) of Elotuzumab in Combination With Bortezomib, Lenalidomide and Dexamethasone
- Primary outcome: Progression-free Survival

## Commentary we found

- YouTube: 6
- X threads: 5
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct01668719

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01668719", "email": "<work email>"}; the inbox owner confirms by the emailed link.